Yahoo Finance

Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO Deficiency

WINNIPEG, MB / ACCESSWIRE / April 23, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and ...
Monthly Prescribing Reference

Oral Pyridoxal 5′-Phosphate Fast Tracked for PNPO Deficiency

MC-1 is an investigational agent that contains pyridoxal 5'-phosphate monohydrate, an active vitamin B6 metabolite. The Food and Drug Administration (FDA) has granted Fast Track designation to MC-1 ...
Nasdaq

Medicure Announces Pivotal Phase 3 Trial IND Filing with FDA for Treatment of Seizures Associated with Pyridox(am)ine 5'-phosphate oxidase (PNPO) Deficiency

WINNIPEG, MB, Jan. 7, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today announced that through its Barbados ...
Finanznachrichten

Medicure, Inc.: Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO Deficiency

The designation was requested based on the potential for MC-1 to address an unmet medical need for PNPO deficiency, a serious and life-threatening condition. Medicure is in the launch phase of its ...